These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 36277213)
1. Validation of Jeong DU; Danadibrata RZ; Marcellinus A; Lim KM Front Physiol; 2022; 13():1009647. PubMed ID: 36277213 [TBL] [Abstract][Full Text] [Related]
2. qInward variability-based Jeong DU; Qashri Mahardika T N; Marcellinus A; Lim KM Front Physiol; 2022; 13():1080190. PubMed ID: 36589462 [TBL] [Abstract][Full Text] [Related]
3. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds. Christophe B Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662 [TBL] [Abstract][Full Text] [Related]
4. Proarrhythmic risk assessment of drugs by dV Jeong DU; Yoo Y; Marcellinus A; Kim KS; Lim KM CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):653-664. PubMed ID: 35579100 [TBL] [Abstract][Full Text] [Related]
5. Considering population variability of electrophysiological models improves the in silico assessment of drug-induced torsadogenic risk. Llopis-Lorente J; Trenor B; Saiz J Comput Methods Programs Biomed; 2022 Jun; 221():106934. PubMed ID: 35687995 [TBL] [Abstract][Full Text] [Related]
6. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z Front Physiol; 2017; 8():917. PubMed ID: 29209226 [TBL] [Abstract][Full Text] [Related]
7. Application of Convolutional Neural Networks Using Action Potential Shape for In-Silico Proarrhythmic Risk Assessment. Jeong DU; Yoo Y; Marcellinus A; Lim KM Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830942 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Drug Proarrhythmicity Using Artificial Neural Networks With Yoo Y; Marcellinus A; Jeong DU; Kim KS; Lim KM Front Physiol; 2021; 12():761691. PubMed ID: 34955882 [TBL] [Abstract][Full Text] [Related]
9. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology. Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629 [TBL] [Abstract][Full Text] [Related]
10. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs. Vicente J; Stockbridge N; Strauss DG J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478 [TBL] [Abstract][Full Text] [Related]
11. Optimization of an Dutta S; Chang KC; Beattie KA; Sheng J; Tran PN; Wu WW; Wu M; Strauss DG; Colatsky T; Li Z Front Physiol; 2017; 8():616. PubMed ID: 28878692 [TBL] [Abstract][Full Text] [Related]
12. Introduction to Park JS; Jeon JY; Yang JH; Kim MG Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576 [TBL] [Abstract][Full Text] [Related]
13. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211 [TBL] [Abstract][Full Text] [Related]
14. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology. Christophe B; Crumb WJ J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs. Han S; Han S; Kim KS; Lee HA; Yim DS Front Pharmacol; 2019; 10():1419. PubMed ID: 31849669 [TBL] [Abstract][Full Text] [Related]
16. Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure. Leishman DJ J Pharmacol Toxicol Methods; 2020; 101():106654. PubMed ID: 31730936 [TBL] [Abstract][Full Text] [Related]
17. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Farkas AS; Nattel S Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805 [TBL] [Abstract][Full Text] [Related]